Previous studies have indicated that the high concentration of the circulating Tie2 ligand Ang2 is associated with poor patient prognosis [16–19], and Ang2/Tie system-targeting antibodies and tyrosine kinase inhibitors are currently in clinical trials, including in those focused on breast cancer [20, 22]. This evidence concerns the gene TEK and breast carcinoma.